Aktuellt
SENASTE
Redeye endorses the positive results from Nanexa’s clinical phase I trial with NEX-20, a long-acting formulation of lenalidomide. We are encouraged to learn that the clinical phase I study with NEX-20 confirmed a release profile of lenalidomide in different doses up to 21 days. We will return with a more thorough comment in our Q2 update, where we will likely nudge up our base case.
LÄS MER
